Kimberly-Clark stock faces EU test after USD 40 billion bid

Kimberly-Clark (ISIN US4943681035) traded at USD 98.07 on Nasdaq on September 23, 2026, down 0.85 percent, while the company offered concessions in its USD 40 billion Kenvue bid. The deal now faces an extended European Union review that could shape Kimberly-Clark's growth strategy.

EU review moves to October

According to Reuters on September 23, 2026, Kimberly-Clark submitted concessions to address antitrust concerns over its acquisition of Kenvue. The European Commission extended its decision deadline to October 13 from September 29.

The remedies were not detailed in the report, but the commission may seek feedback from rivals and customers before accepting them, requesting additional measures, or opening a full four-month investigation. Reuters also reported that Kimberly-Clark is prepared to sell assets to ease competition concerns.

Quarterly figures set a hurdle

Kimberly-Clark's latest reported quarter showed USD 4.19 billion in revenue and quarterly EPS of USD 1.80, according to MarketBeat in its Q2 2026 earnings summary. Revenue was up 0.6 percent from the same quarter a year earlier, while EPS was below the USD 2.01 consensus by USD 0.21.

That comparison gives the acquisition review extra importance: the Kenvue transaction is designed to expand Kimberly-Clark's consumer health exposure, while the latest earnings showed a narrower margin for execution. The next regulatory deadline therefore matters alongside the company's operating recovery.

Stock remains 21.74 percent below high

At USD 98.07 on September 23, 2026, Kimberly-Clark stock stood 21.74 percent below its 52-week high of USD 125.32 and USD 5.65 above its 52-week low of USD 92.42. The USD 32,554,185,650 market capitalization places the regulatory decision alongside a measurable valuation reset.